Aequus Pharmaceuticals (AQSZF) is a growing specialty pharmaceutical company with an increasing pipeline of commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry. My latest article from 4th May 2020 summarized the status of the full Aequus pipeline including the company's business strategy in detail. For readers not being familiar with Aequus yet, I recommend the latest article as a pre-read. In today's article, I will provide an incremental update and will focus on the projection of future revenue in order to verify the investment opportunity.